Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mo-Rez versus physician's choice standard of care in platinum-resistant ovarian cancer
NL-OMON61626Phase 3Not yet recruiting
- Sponsor
- GSK
- Start
- Sep 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) comparing Mocertatug rezetecan with Physician's choice standard of care (2 arms). Primary endpoints: Progression-free survival by blinded independent central review and Overall survival. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
mocertatug rezetecan
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NL-OMON61626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61626.